Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Journal
Hematology. American Society of Hematology. Education Program
ISSN: 1520-4383
Titre abrégé: Hematology Am Soc Hematol Educ Program
Pays: United States
ID NLM: 100890099
Informations de publication
Date de publication:
10 12 2021
10 12 2021
Historique:
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
16
2
2022
Statut:
ppublish
Résumé
The adage for smoldering myeloma (SMM) has been to observe without treatment, until criteria for active multiple myeloma were satisfied. Definitions and risk stratification models have become more sophisticated, with prognostication tailored to include high-risk cytogenetics as per the most recent International Myeloma Working Group 2020 risk model. Moreover, progress in defining genomic evolution and changes in the bone marrow microenvironment through the monoclonal continuum have given insight into the complexities underlying the different patterns of progression observed in SMM. Given recent data showing improved progression-free survival with early intervention in high-risk SMM, the current dilemma is focused on how these patients should be treated. This case-based article maps the significant advancements made in the diagnosis and risk stratification of SMM. Data from landmark clinical trials will also be discussed, and ongoing trials are summarized. Ultimately, we outline our approach to SMM and hope to impart to the reader a sound concept of the current clinical management of SMM.
Identifiants
pubmed: 34889380
pii: 482954
doi: 10.1182/hematology.2021000304
pmc: PMC8791169
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-681Informations de copyright
Copyright © 2021 by The American Society of Hematology.
Références
Leukemia. 2013 Mar;27(3):680-5
pubmed: 22902364
Blood Cancer J. 2020 Feb 17;10(2):19
pubmed: 32066732
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
JAMA Oncol. 2021 Jan 1;7(1):132-134
pubmed: 33211080
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Blood. 2016 Mar 3;127(9):1151-62
pubmed: 26668134
Lancet Oncol. 2017 Apr;18(4):e206-e217
pubmed: 28368259
Blood Adv. 2018 Nov 27;2(22):3149-3154
pubmed: 30463914
Leukemia. 2020 Jul;34(7):1840-1852
pubmed: 32024950
N Engl J Med. 2013 Aug 1;369(5):438-47
pubmed: 23902483
Front Oncol. 2020 Jan 24;9:1513
pubmed: 32039008
Blood Cancer J. 2017 Oct 20;7(10):e618
pubmed: 29053158
Leukemia. 2018 Jun;32(6):1427-1434
pubmed: 29463830
Blood Cancer J. 2016 Oct 21;6(10):e486
pubmed: 27768092
J Clin Oncol. 2020 Jul 20;38(21):2380-2389
pubmed: 32442065
Am J Hematol. 2021 Mar 1;96(3):E63-E65
pubmed: 33264449
N Engl J Med. 1980 Jun 12;302(24):1347-9
pubmed: 7374679
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Nat Cancer. 2020 May;1(5):493-506
pubmed: 33409501
Leukemia. 2014 Dec;28(12):2402-3
pubmed: 25079172
Leukemia. 2019 Feb;33(2):457-468
pubmed: 30046162
Leukemia. 2016 Feb;30(2):417-22
pubmed: 26490489
Leukemia. 2013 Aug;27(8):1738-44
pubmed: 23515097
Leukemia. 2013 Apr;27(4):941-6
pubmed: 23183428
Lancet Oncol. 2016 Aug;17(8):1127-1136
pubmed: 27402145
Nat Commun. 2021 Jan 12;12(1):293
pubmed: 33436579
Mayo Clin Proc. 2012 Nov;87(11):1071-9
pubmed: 22883742
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
J Clin Oncol. 2020 Jul 20;38(21):2363-2365
pubmed: 32463739
J Clin Oncol. 2020 Apr 10;38(11):1126-1137
pubmed: 31652094
Blood Cancer J. 2016 Jul 29;6(7):e454
pubmed: 27471870
N Engl J Med. 2011 Aug 4;365(5):474-5
pubmed: 21812699
Blood Cancer J. 2020 Oct 16;10(10):102
pubmed: 33067414
Hemasphere. 2019 Jun 30;3(Suppl):
pubmed: 35309815
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Blood Cancer J. 2018 Jun 12;8(6):59
pubmed: 29895887
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818
N Engl J Med. 2013 Oct 31;369(18):1762-3
pubmed: 24171527